News | May 04, 2026
Bristol Myers Squibb begins 2026 with growth momentum
The company’s Growth Portfolio delivered $6.2 billion in revenue
The company’s Growth Portfolio delivered $6.2 billion in revenue
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
But acquisition charges drag earnings into loss
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Health innovations are viewed more positively than food and agricultural technologies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
